Detalhe da pesquisa
1.
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.
Nat Med
; 29(8): 2019-2029, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37460756
2.
Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
Hemasphere
; 2(6): e157, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31723795